Pycnogenol (French maritime pine bark extract) trials recruiting now
2 registrations that name pycnogenol as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
Not yet recruitingNCT07266571
Pycnogenol (French Maritime Pine Bark) for the Treatment of Gulf War Illness
No phase
University of Alabama at Birmingham
About 20 people
Starts Nov 1, 2026 (estimated)
In plain words A study of pycnogenol in male participants 18 and older, run by University of Alabama at Birmingham. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Gulf War Syndrome.
Meet the Kansas GWI case definition
Meet the CDC GWI case definition
Able to commit to a 12-month study
Male
1 more inclusion criterion and the exclusion criteria are on the listing.
The purpose of this research study is to determine how pycnogenol may reduce Gulf War Illness (GWI) symptom severity. The study will also examine the safety of this treatment and determine the optimal dosage. The investigators believe that GWI involves inflammation in the body and brain that causes fatigue, pain, cognitive disruption, and other symptoms. Botanicals that reduce inflammation may help treat GWI.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07855198
The Improving Effects of French Maritime Pine Bark Extract on Antioxidation and Anti-inflammation a in Post-menopausal Women Based on Nutrigenomic Approach
No phase
Taipei Medical University
About 46 people
Starts Sep 7, 2026 (estimated)
In plain words A study of pycnogenol in female participants 40 to 75, run by Taipei Medical University. It plans to enroll about 46 people and lists no sites yet.
Free from chronic diseases and not taking regular medications.
The exclusion criteria are on the listing.
What it tests, as registered
French maritime pine bark extract; Placebo
Registered summary
The goal of this clinical trial is to investigate whether French maritime pine bark extract (FMPBE) supplementation can improve antioxidant capacity and reduce inflammation in postmenopausal women aged 40-75 years. The main questions it aims to answer are: Does FMPBE supplementation improve antioxidant status and reduce oxidative stress? Does FMPBE supplementation reduce inflammatory responses and affect related gene expression? Researchers will compare an FMPBE treatment group with a placebo group. The full summary is on the listing.